Working… Menu

Rosiglitazone Adjunctive Therapy for Severe Malaria in Children (ROSI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02694874
Recruitment Status : Active, not recruiting
First Posted : March 1, 2016
Last Update Posted : January 27, 2021
University Health Network, Toronto
Barcelona Institute for Global Health
Information provided by (Responsible Party):
Centro de Investigacao em Saude de Manhica

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : March 2020
Estimated Study Completion Date : December 2021